MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-13-2025
AgeX Therapeutics Operating Income 2011-2025 | AGE
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income AgeX Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -9.89 M | -6.98 M | -7.93 M | -10.1 M | -12.6 M | -11.2 M | -6.66 M | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -6.66 M | -12.6 M | -9.34 M |
Quarterly Operating Income AgeX Therapeutics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -6.39 M | -5.56 M | -5.86 M | - | -5.31 M | -3.87 M | -2.32 M | - | -1.46 M | -945 K | -962 K | - | -1.55 M | -1.59 M | -2.05 M | - | -1.67 M | -2.2 M | -2.19 M | - | -2.4 M | -2.37 M | -3.01 M | - | -3.28 M | -3.44 M | -3.12 M | - | -2.2 M | -2.13 M | -3.55 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -945 K | -6.39 M | -2.89 M |
Operating Income of other stocks in the Biotechnology industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-508 M | - | 2.43 % | $ 254 M |  Germany |
 |
Pharming Group N.V.
PHAR
|
66.7 M | $ 17.91 | -1.0 % | $ 7.59 B |  Niderland |
 |
Arbutus Biopharma Corporation
ABUS
|
-78.1 M | $ 4.78 | -0.31 % | $ 793 M |  Canada |
 |
Aclaris Therapeutics
ACRS
|
-142 M | $ 3.03 | -0.49 % | $ 234 M |  USA |
 |
Aeglea BioTherapeutics
AGLE
|
-209 M | - | - | $ 1.01 B | USA |
 |
Alpine Immune Sciences
ALPN
|
-58.1 M | - | - | $ 2.17 B | USA |
 |
AlloVir
ALVR
|
-65.4 M | - | 4.14 % | $ 49.1 M | USA |
 |
Midatech Pharma plc
MTP
|
-7 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Biophytis SA
BPTS
|
-26.8 M | - | -13.47 % | $ 169 M |  France |
 |
Ampio Pharmaceuticals
AMPE
|
-33.3 M | - | -11.43 % | $ 502 K | USA |
 |
Applied Molecular Transport
AMTI
|
-127 M | - | - | $ 10.1 M | USA |
 |
Ascendis Pharma A/S
ASND
|
-452 M | $ 209.39 | -1.61 % | $ 5 B |  Danmark |
 |
Aptevo Therapeutics
APVO
|
-24.6 M | $ 0.6 | -35.8 % | $ 166 K | USA |
 |
BioVie
BIVI
|
-18.1 M | $ 1.2 | -5.51 % | $ 1.77 M | USA |
 |
Athersys
ATHX
|
-87.1 M | - | 3.77 % | $ 22.4 M | USA |
 |
Avenue Therapeutics
ATXI
|
-11.3 M | - | -52.27 % | $ 4.45 M | USA |
 |
ARCA biopharma
ABIO
|
-88.1 M | - | 1052.0 % | $ 415 M | USA |
 |
AVROBIO
AVRO
|
10.2 M | - | 1083.1 % | $ 745 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-8.13 M | $ 0.22 | 24.46 % | $ 479 M |  Israel |
 |
Acasti Pharma
ACST
|
-16.7 M | - | 4.01 % | $ 150 M | Canada |
 |
Adaptimmune Therapeutics plc
ADAP
|
-140 M | - | -15.15 % | $ 60.3 M | Britain |
 |
BioDelivery Sciences International
BDSI
|
37.1 M | - | -4.8 % | $ 255 M | USA |
 |
Albireo Pharma
ALBO
|
-123 M | - | -0.23 % | $ 916 M | USA |
 |
BioNTech SE
BNTX
|
15.3 B | $ 94.72 | -0.33 % | $ 27.2 B | Germany |
 |
Amphastar Pharmaceuticals
AMPH
|
205 M | $ 27.09 | 1.04 % | $ 1.31 B | USA |
 |
BeiGene, Ltd.
BGNE
|
-568 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Anika Therapeutics
ANIK
|
-87.6 M | $ 9.6 | 1.27 % | $ 141 M | USA |
 |
Bellicum Pharmaceuticals
BLCM
|
-27 M | - | -9.72 % | $ 5.89 M | USA |
 |
Berkeley Lights
BLI
|
-98.1 M | - | -7.31 % | $ 87 M | USA |
 |
bluebird bio
BLUE
|
-244 M | - | - | $ 546 M | USA |
 |
Arena Pharmaceuticals
ARNA
|
-624 M | - | -6.81 % | $ 3.04 B | USA |
 |
Acer Therapeutics
ACER
|
-24.6 M | - | 2.71 % | $ 14 M | USA |
 |
Calithera Biosciences
CALA
|
-115 M | - | -10.95 % | $ 876 K | USA |
 |
Axon Enterprise
AXON
|
58.5 M | $ 584.81 | -1.07 % | $ 44.3 B | USA |
 |
Cellectar Biosciences
CLRB
|
-39 M | $ 2.53 | -8.33 % | $ 30.9 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-37.5 M | - | - | $ 7.46 M | Israel |
 |
Aytu BioScience
AYTU
|
-7.83 M | $ 2.44 | -3.56 % | $ 15.3 M | USA |
 |
AstraZeneca PLC
AZN
|
1.06 B | $ 92.79 | 0.37 % | $ 96.9 B | Britain |
 |
Acorda Therapeutics
ACOR
|
-265 M | - | -24.86 % | $ 820 K | USA |
 |
Catalyst Biosciences
CBIO
|
-67.2 M | $ 12.33 | -0.29 % | $ 812 M | USA |
 |
Brickell Biotech
BBI
|
-6.36 M | - | -5.38 % | $ 6.06 M | USA |
 |
Burford Capital Limited
BUR
|
242 M | $ 9.1 | 1.0 % | $ 1.48 B | Britain |
 |
Celldex Therapeutics
CLDX
|
-195 M | $ 26.29 | -2.01 % | $ 1.69 M | USA |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
-704 M | $ 11.07 | 2.45 % | $ 716 M | USA |